JP2011529917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529917A5 JP2011529917A5 JP2011521360A JP2011521360A JP2011529917A5 JP 2011529917 A5 JP2011529917 A5 JP 2011529917A5 JP 2011521360 A JP2011521360 A JP 2011521360A JP 2011521360 A JP2011521360 A JP 2011521360A JP 2011529917 A5 JP2011529917 A5 JP 2011529917A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- group
- alkynyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000000304 alkynyl group Chemical group 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- -1 amino, hydroxyl Chemical group 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 7
- 150000001602 bicycloalkyls Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims 4
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 claims 4
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 3
- 125000005096 aminoalkylaminocarbonyl group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- 125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 claims 2
- 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 claims 2
- 125000003860 C1-C20 alkoxy group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 125000005030 pyridylthio group Chemical group N1=C(C=CC=C1)S* 0.000 claims 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- 102000009346 Adenosine receptors Human genes 0.000 claims 1
- 108050000203 Adenosine receptors Proteins 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 241000159243 Toxicodendron radicans Species 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 0 CC(*)*(C)C1=C(*)*(C)C(C*)*C1C Chemical compound CC(*)*(C)C1=C(*)*(C)C(C*)*C1C 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8558808P | 2008-08-01 | 2008-08-01 | |
| US61/085,588 | 2008-08-01 | ||
| PCT/US2009/052439 WO2010014921A2 (en) | 2008-08-01 | 2009-07-31 | A3 adenosine receptor antagonists and partial agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529917A JP2011529917A (ja) | 2011-12-15 |
| JP2011529917A5 true JP2011529917A5 (cg-RX-API-DMAC7.html) | 2012-07-12 |
| JP5431476B2 JP5431476B2 (ja) | 2014-03-05 |
Family
ID=41111356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521360A Expired - Fee Related JP5431476B2 (ja) | 2008-08-01 | 2009-07-31 | A3アデノシン受容体アンタゴニストおよびa3アデノシン受容体部分アゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8796291B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2331542B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5431476B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009276411B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2732320C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010014921A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010014921A2 (en) | 2008-08-01 | 2010-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
| AU2009231978C1 (en) * | 2008-03-31 | 2014-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as A3 adenosine receptor- selective agonists |
| US8916570B2 (en) * | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| WO2011123518A1 (en) | 2010-03-31 | 2011-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
| RS55348B1 (sr) | 2010-04-19 | 2017-03-31 | Oryzon Gnomics S A | Inhibitori lizin specifične demetilaze-1 i njihova upotreba |
| DK2598482T3 (en) | 2010-07-29 | 2018-06-14 | Oryzon Genomics Sa | ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| EP2750671A2 (en) * | 2011-05-19 | 2014-07-09 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| WO2012156531A2 (en) * | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| AU2012324803B9 (en) | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| US9469597B2 (en) | 2011-10-20 | 2016-10-18 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| JP2013256491A (ja) * | 2012-05-14 | 2013-12-26 | Kyoto Univ | 不安定プラークへの選択的集積性に優れる化合物 |
| WO2015080940A1 (en) | 2013-11-27 | 2015-06-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| ES2578363B1 (es) | 2015-01-22 | 2017-01-31 | Palobiofarma, S.L. | Moduladores de los receptores A3 de adenosina |
| CN109310695B (zh) | 2016-04-21 | 2022-04-01 | 阿斯特罗赛特制药公司 | 治疗神经和心血管病况的化合物和方法 |
| ES2676535B1 (es) | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
| US11839615B2 (en) | 2018-02-09 | 2023-12-12 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating addiction and related disorders |
| EP3856741A4 (en) | 2018-09-26 | 2022-06-22 | Astrocyte Pharmaceuticals, Inc. | POLYMORPHOUS COMPOUNDS AND USES THEREOF |
| US12397010B2 (en) | 2019-02-15 | 2025-08-26 | Saint Louis University | Treatment of chronic headaches |
| WO2022040241A1 (en) | 2020-08-17 | 2022-02-24 | Biointervene, Inc. | A3 adenosine receptor agonists for use in medicine |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773423A (en) * | 1993-07-13 | 1998-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| US5688774A (en) * | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
| JP4431638B2 (ja) * | 1996-01-29 | 2010-03-17 | アメリカ合衆国 | ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途 |
| US5840728A (en) * | 1996-08-07 | 1998-11-24 | United States Of America As Represented By The Department Of Health And Human Services | Conformationally locked nucleoside analogs as antiherpetic agents |
| CN1265572A (zh) * | 1997-04-30 | 2000-09-06 | 莱兰斯坦福初级大学评议会 | 活体内造影细胞死亡的方法 |
| WO1998050047A1 (en) * | 1997-05-09 | 1998-11-12 | Trustees Of The University Of Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| DE69837095T2 (de) * | 1997-09-03 | 2007-11-22 | Immunomedics, Inc. | Fluorierung von proteinen und peptiden für positronemissionstomographie |
| EP1096975B1 (en) * | 1998-07-16 | 2005-03-16 | The Trustees Of The University Of Pennsylvania | Use of a3 adenosine receptor antagonists in the manufacture of a medicament for reducing intraocular pressure |
| US6921825B2 (en) * | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
| US6586413B2 (en) * | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| ATE336492T1 (de) * | 2000-01-14 | 2006-09-15 | Us Gov Health & Human Serv | Methonocarbacycloalkylanaloga von nucleosiden |
| GB2372742A (en) * | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
| US20030143282A1 (en) * | 2002-01-28 | 2003-07-31 | Pnina Fishman | Adenosine A3 receptor agonist |
| US20060100168A1 (en) * | 2002-09-30 | 2006-05-11 | The Trustee Of Boston University | Method of treating cancer using adenosine and its analogs |
| KR20070050484A (ko) * | 2004-09-09 | 2007-05-15 | 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | A1 및 a3 아데노신 수용체 아고니스트로서의 퓨린 유도체 |
| WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| US20090192077A1 (en) | 2005-04-15 | 2009-07-30 | Shizuko Sei | North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus |
| US7381714B2 (en) | 2005-05-19 | 2008-06-03 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| US20090221523A1 (en) | 2005-05-25 | 2009-09-03 | Tseng Christopher K | North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses |
| WO2007002139A2 (en) | 2005-06-22 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Neuroprotection of retinal ganglion cells |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| WO2007043054A1 (en) | 2005-10-12 | 2007-04-19 | Can-Fite Biopharma Ltd. | Treatment and monitoring disease state of liver cancer |
| JP5339916B2 (ja) | 2005-11-30 | 2013-11-13 | キャン−ファイト・バイオファーマ・リミテッド | 骨関節炎の治療におけるa3アデノシン受容体アゴニストの使用 |
| EP1798233A1 (en) | 2005-12-19 | 2007-06-20 | Faust Pharmaceuticals | Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof |
| AU2006336834B2 (en) | 2006-01-27 | 2009-12-10 | Can-Fite Biopharma Ltd. | Adenosine A3 receptor agonists for the treatment of dry eye disorders |
| EP2001881A2 (en) | 2006-03-07 | 2008-12-17 | Endacea, Inc. | Compositions and methods for treating respiratory disorders |
| GB0607944D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| ES2526713T3 (es) * | 2006-05-23 | 2015-01-14 | University Of Connecticut | Derivados de N-metanocarba para tratar enfermedades cardiacas |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| US20100062994A1 (en) | 2006-07-14 | 2010-03-11 | Santaris Pharma A/S | Adenosine Receptor Antagonists |
| WO2008023362A2 (en) * | 2006-08-21 | 2008-02-28 | Can-Fite Biopharma Ltd. | Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer |
| WO2008058238A2 (en) | 2006-11-08 | 2008-05-15 | Thomas Jefferson University | Adenosine a1 and a3 receptor gene sequence variations for predicting disease outcome and treatment outcome |
| WO2008055711A2 (en) | 2006-11-09 | 2008-05-15 | Centre De Recherche Public De La Sante | Use of an adenosine antagonist |
| WO2008056361A1 (en) | 2006-11-09 | 2008-05-15 | Can-Fite Biopharma Ltd. | A biological marker for psoriasis |
| GB0625100D0 (en) | 2006-12-15 | 2007-01-24 | Univ Murcia | Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection |
| US8916570B2 (en) * | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| AU2009231978C1 (en) * | 2008-03-31 | 2014-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as A3 adenosine receptor- selective agonists |
| WO2010014921A2 (en) | 2008-08-01 | 2010-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
| US9181253B2 (en) * | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| EP2507241A1 (en) * | 2009-12-02 | 2012-10-10 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Methanocarba adenosine derivatives and dendrimer conjugates thereof |
| WO2012145098A1 (en) * | 2011-04-21 | 2012-10-26 | Saint Louis University | Use of adenosine a3 receptor agonists for treatment of neuropathic pain |
-
2009
- 2009-07-31 WO PCT/US2009/052439 patent/WO2010014921A2/en not_active Ceased
- 2009-07-31 US US13/056,997 patent/US8796291B2/en not_active Expired - Fee Related
- 2009-07-31 EP EP09791060.8A patent/EP2331542B1/en not_active Not-in-force
- 2009-07-31 CA CA2732320A patent/CA2732320C/en not_active Expired - Fee Related
- 2009-07-31 JP JP2011521360A patent/JP5431476B2/ja not_active Expired - Fee Related
- 2009-07-31 AU AU2009276411A patent/AU2009276411B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022050538A (ja) | プロスタサイクリン(pgi2)受容体に関連する障害の処置に有用なpgi2受容体の調節因子 | |
| KR102441242B1 (ko) | 2-(2,4-디플루오로페닐)-1,1-디플루오로-1-(5-치환된-피리딘-2-일)-3-(1h-테트라졸-1-일)프로판-2-올 및 이의 제조방법 | |
| JOP20210001A1 (ar) | مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2 | |
| EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
| JP2020502115A5 (cg-RX-API-DMAC7.html) | ||
| RU2013114351A (ru) | Пестицидные композиции | |
| RU2006120441A (ru) | Комбинация действующих веществ с инсектицидными свойствами | |
| JP2011529964A5 (cg-RX-API-DMAC7.html) | ||
| WO2021076688A1 (en) | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases | |
| BR112013003245B1 (pt) | Derivados de heteroarilpiperidina e -piperazina como fungicidas e composição para controlar fungos fitopatogênicos prejudiciais os compreendendo e uso dos mesmos, método para controlar fungos fitopatogênicos prejudiciais, bem como processo para produzir composições para controlar fungos fitopatogênicos prejudiciais | |
| JP2009519243A5 (cg-RX-API-DMAC7.html) | ||
| JP2006505543A5 (cg-RX-API-DMAC7.html) | ||
| RU2010107171A (ru) | Фунгицидные n-циклоалкилбензилтиокарбоксамиды или n-циклоалкилбензил-n, -замещенные амидиновые производные | |
| HUP0105098A2 (hu) | Fungicid hatású N2-fenil-amidin származékok, intermedierjeik és alkalmazásuk | |
| CA2766199A1 (en) | Thiazolylpiperidine derivates as fungicides | |
| JP2019535723A5 (cg-RX-API-DMAC7.html) | ||
| RU2011136250A (ru) | Низкомолекулярное полисульфатированное производное гиалуроновой кислоты и содержащее его лекарственное средство | |
| JP2007505931A5 (cg-RX-API-DMAC7.html) | ||
| JP2020502052A5 (cg-RX-API-DMAC7.html) | ||
| CA2722734A1 (en) | 3,4-substituted piperidine derivatives as renin inhibitors | |
| JP2019532067A5 (cg-RX-API-DMAC7.html) | ||
| WO2019048988A1 (en) | Novel fungidal heterocyclic compounds | |
| JP2010534246A5 (cg-RX-API-DMAC7.html) | ||
| JP2005511602A5 (cg-RX-API-DMAC7.html) | ||
| JP4464140B2 (ja) | 殺菌剤として有用なケイ素化フェニルアミド誘導体 |